Logo

CYTK

Cytokinetics, Incorporated

CYTK

Cytokinetics, Incorporated • NASDAQ
$68.13 ▼ -0.03% (-0.02)
Market Cap $8.11 B
52w High $69.33
52w Low $29.31
Dividend Yield 0%
P/E -10.81
Volume 415.64K
Outstanding Shares 118.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.936M ▼ $166.012M ▼ $-306.178M ▼ -15.815K% ▼ $-2.55 ▼ $-277.177M ▼
Q2-2025 $66.769M ▲ $175.99M ▲ $-134.37M ▲ -201.246% ▲ $-1.12 ▲ $-107.82M ▲
Q1-2025 $1.579M ▼ $57.369M ▼ $-161.376M ▼ -10.22K% ▼ $-1.36 ▼ $-136.13M ▼
Q4-2024 $16.927M ▲ $62.338M ▲ $-150.02M ▲ -886.276% ▲ $-1.27 ▲ $-125.043M ▲
Q3-2024 $463K $56.652M $-160.545M -34.675K% $-1.36 $-135.836M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $962.535M ▲ $1.437B ▲ $1.958B ▲ $-521.123M ▼
Q2-2025 $858.135M ▼ $1.226B ▼ $1.594B ▲ $-368.72M ▼
Q1-2025 $938.218M ▼ $1.264B ▼ $1.53B ▼ $-266.413M ▼
Q4-2024 $1.076B ▲ $1.402B ▼ $1.537B ▲ $-135.372M ▼
Q3-2024 $1.012B $1.436B $1.45B $-13.911M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-306.178M ▼ $-107.505M ▲ $-70.979M ▼ $330.466M ▲ $152.028M ▲ $-116.859M ▲
Q2-2025 $-134.37M ▲ $-128.236M ▲ $52.881M ▼ $78.533M ▲ $2.496M ▲ $-132.381M ▲
Q1-2025 $-161.376M ▼ $-131.617M ▼ $105.956M ▼ $4.754M ▲ $-21.177M ▼ $-137.281M ▼
Q4-2024 $-150.02M ▲ $-65.57M ▲ $110.863M ▲ $2.384M ▼ $47.969M ▲ $-66.86M ▲
Q3-2024 $-160.545M $-101.5M $-45.053M $3.425M $-143.254M $-103.955M

Revenue by Products

Product Q2-2024Q3-2024Q2-2025Q3-2025
Collaboration Revenues
Collaboration Revenues
 $0 ▲$0 ▲$0 ▲$0 ▲
Research And Development
Research And Development
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Cytokinetics looks like a classic late-stage biotech: essentially no recurring product revenue yet, but very heavy spending on research and development and supporting functions. Losses have grown meaningfully over the past five years as the company pushed multiple drug candidates through late-stage trials. The trend is clear: expenses are rising faster than any near-term income, and per‑share losses have widened, reflecting an aggressive investment phase ahead of potential commercialization rather than a mature, profit-oriented business model.

Balance Sheet

Balance Sheet The balance sheet shows a company that has steadily built up its asset base but has done so alongside a sizable increase in debt and a swing to negative shareholders’ equity. In simple terms, obligations now exceed recorded equity, which is not unusual for a high‑spend biotech without products, but it does underscore financial risk if key programs disappoint. That said, more recent disclosures point to a very large cash and investment cushion raised through financings and partnerships, which improves near‑term staying power even though leverage and accumulated losses remain a concern.

Cash Flow

Cash Flow Cash flow is dominated by outflows from operations, driven by clinical trials, staff, and overhead, with very little spent on physical assets. Free cash flow has been consistently negative and has trended more deeply into the red as development efforts have scaled up. The business is clearly in cash‑consuming mode and remains dependent on external funding sources—equity raises, debt, and collaborations—to sustain its pipeline until any future product launches can begin to offset this burn.

Competitive Edge

Competitive Edge Competitively, Cytokinetics occupies a specialized niche in muscle biology, especially cardiac muscle, with a depth of science and intellectual property that is unusual for a company its size. Its lead drug, aficamten, targets a well‑defined genetic heart condition where an existing rival therapy from a large pharmaceutical company is already on the market, but aficamten may offer a more favorable safety and dosing profile based on current data. This could position it as a strong challenger, yet it faces a well‑funded incumbent and the usual uncertainties around regulators, pricing, and physician adoption. The company’s focus and know‑how form a real moat, but its commercial footing is still unproven.

Innovation and R&D

Innovation and R&D Innovation and R&D are the heart of Cytokinetics. The company has spent heavily to build a platform around precise control of muscle contraction, producing both cardiac myosin inhibitors and activators from the same scientific base. Aficamten is the flagship, but earlier‑stage assets like ulacamten and CK‑089 show that the platform is being extended into other forms of heart failure and skeletal muscle disease. The long‑term vision is ambitious, with multiple novel drugs across several indications, but prior late‑stage setbacks highlight that the path is bumpy and success is far from guaranteed. The upside is a differentiated, deep pipeline; the trade‑off is high technical and regulatory risk.

Summary

Overall, Cytokinetics is a high‑risk, high‑potential biotech that is still firmly in the investment phase. Financially, it is loss‑making and cash‑burning, with a history of rising expenses, growing deficits, and reliance on external capital, though recent fundraising has strengthened its cash position. Strategically, it has a distinctive scientific focus and a potentially best‑in‑class lead drug in a defined cardiovascular niche, backed by a broader pipeline that leverages the same core biology. The company’s future will largely be determined by whether aficamten gains approval and commercial traction, and whether follow‑on programs can convert heavy R&D spending into a durable, diversified franchise over time.

NEWS

November 18, 2025 · 4:00 PM UTC

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Read more

November 17, 2025 · 7:39 PM UTC

CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Read more

November 17, 2025 · 3:59 PM UTC

CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025

Read more

November 17, 2025 · 3:48 PM UTC

Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK

Read more

November 17, 2025 · 1:44 PM UTC

CYTK DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK

Read more